Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Stereotactic Aspiration Combined With Tenecteplase for Acute Pontine Hemorrhage

10 de noviembre de 2026 actualizado por: Dr. Yong Cao, Beijing Tiantan Hospital

A Multicenter, Randomized, Open-Label, Blinded-Endpoint Clinical Trial of Neuronavigation-Guided Stereotactic Aspiration Combined With Tenecteplase for Acute Brainstem Hemorrhage

This multicenter, randomized, open-label, blinded-endpoint clinical study aims to evaluate the safety, feasibility, and potential clinical benefits of neuronavigation-guided stereotactic hematoma aspiration combined with tenecteplase in patients with acute primary brainstem hemorrhage.A total of 140 patients will be randomly assigned in a 1:1 ratio to receive either stereotactic hematoma aspiration combined with tenecteplase and standard medical treatment or standard medical treatment alone.The primary outcome is the proportion of patients with a Glasgow Coma Scale (GCS) score greater than 8 at 90 days. Safety outcomes include mortality, symptomatic rebleeding, and intracranial infection.

Descripción general del estudio

Tipo de estudio

Intervencionista

Inscripción (Estimado)

140

Fase

  • No aplica

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Estudio Contacto

  • Nombre: Yong Cao
  • Número de teléfono: +86 13601362306
  • Correo electrónico: caoyong@bjth.org

Ubicaciones de estudio

    • Beijing Municipality
      • Beijing, Beijing Municipality, Porcelana, 100070
        • Reclutamiento
        • Beijing Tiantan Hospital, Capital Medical University
        • Contacto:
          • Yong Cao
          • Número de teléfono: +86 13601362306
          • Correo electrónico: caoyong@bjth.org

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 79 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Age ≥18 years and <80 years.
  • Diagnostic CT completed within 24 hours after symptom onset. Patients with unknown onset time will be excluded. For patients with symptoms first noted during sleep, the time last known well will be considered the onset time.
  • Acute primary brainstem hemorrhage confirmed by head CT, with the predominant hematoma location in the pons (>50% of the hematoma located in the pons); hematoma volume 5-10 mL as measured by the ABC/2 method. The hematoma must be located within the brainstem parenchyma rather than primarily within the ventricles, although extension into the third or fourth ventricle is permitted. For unilateral hemorrhage, a hematoma volume of 3-5 mL is permitted.
  • A repeat CT scan performed 6 hours after symptom onset confirms that the hematoma volume remains within the eligibility range.
  • Glasgow Coma Scale (GCS) score ≥5 and <12 at enrollment.
  • Randomization initiated between 6 and 12 hours after the diagnostic CT.
  • Systolic blood pressure (SBP) <180 mmHg maintained during the 6 hours immediately before randomization.
  • Pre-stroke modified Rankin Scale (mRS) score of 0-1.
  • Voluntary participation in the study with written informed consent provided by the participant or legally authorized representative, as applicable.

Exclusion Criteria:

  • Supratentorial hemorrhage, posterior fossa hemorrhage, or cerebellar hemorrhage.
  • Signs of extremely severe disease, including bilaterally fixed and dilated pupils, persistent decerebrate rigidity, or loss of spontaneous respiration.
  • The predominant portion of the hematoma involves the midbrain or medulla.
  • Brainstem hemorrhage secondary to another cerebrovascular or neurological disorder, including cerebral vascular malformation, intracranial aneurysm, other cerebrovascular abnormalities, moyamoya disease, hemorrhagic transformation of ischemic stroke, or hemorrhage related to a neurological tumor.
  • Unstable infratentorial space-occupying lesion, transtentorial herniation, or foramen magnum herniation.
  • Previous history of brainstem hemorrhage.
  • Irreversible brainstem dysfunction, defined as a GCS score ≤4 or ≥12.
  • An indication for craniotomy because of either: (a) progressive deterioration of consciousness; or (b) preoperative cerebral herniation, including signs associated with foramen magnum herniation or uncal herniation.
  • CT evidence indicating a high risk of rebleeding, including a spot sign.
  • Platelet count <100,000/mL or international normalized ratio (INR) >1.4.
  • Any irreversible coagulation disorder, including hemophilia or von Willebrand disease, use of anticoagulants such as warfarin, or a known disorder of clot formation, including a hypercoagulable state.
  • Inability to maintain INR ≤1.4 despite treatment with short- or long-acting hemostatic agents, including recombinant factor VIIa, fresh frozen plasma, or vitamin K.
  • Requirement for long-term anticoagulation. Patients who can undergo temporary reversal of anticoagulation but cannot discontinue warfarin or other anticoagulants for the subsequent 30 days will be excluded.
  • Use within 1 week before symptom onset of dabigatran, apixaban, rivaroxaban, tirofiban, ticagrelor, cilostazol, or clopidogrel.
  • Internal bleeding involving the retroperitoneal, gastrointestinal, or genitourinary systems, or respiratory tract bleeding.
  • Superficial bleeding at a vascular access site (e.g., venous cutdown or arterial puncture) or surgical site.
  • Positive urine or serum pregnancy test in a premenopausal woman without documented surgical sterilization.
  • Known hypersensitivity to tenecteplase.
  • Previous participation in this study with completed randomization.
  • Concurrent participation in another interventional medical study or clinical trial. Participation in an observational study, natural history study, or epidemiological study without an interventional component is permitted.
  • Before randomization, the participant is not expected to survive through the Day 365 follow-up, or has requested do-not-resuscitate (DNR) or do-not-intubate (DNI) status.
  • Any serious concomitant disease expected to substantially affect prognosis, including severe hepatic, renal, gastrointestinal, respiratory, cardiovascular, endocrine, immune, or hematologic disease.
  • Presence of a mechanical prosthetic heart valve. A bioprosthetic heart valve is permitted.
  • Known embolic risk, including a history of left-sided intracardiac thrombus, mitral stenosis with atrial fibrillation, acute pericarditis, or subacute bacterial endocarditis. Atrial fibrillation without mitral stenosis is permitted.
  • Any condition requiring immediate emergency treatment outside the study protocol, including bilaterally fixed and dilated pupils, persistent decerebrate rigidity, loss of spontaneous respiration, signs of cerebral herniation, progressive respiratory or circulatory failure, or a multidisciplinary determination that immediate craniotomy for hematoma evacuation, decompressive craniectomy, emergency external ventricular drainage, or other emergency treatment is required. Study screening and randomization must not delay necessary emergency treatment.
  • The participant requests conservative treatment or conventional open microsurgical treatment.

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Tratamiento
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Único

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Stereotactic Aspiration Combined With Tenecteplase

Participants will receive neuronavigation-guided stereotactic hematoma aspiration followed by intralesional tenecteplase administration, in addition to standard medical treatment.

Neuronavigation-guided stereotactic hematoma aspiration and catheter drainage will be performed within 6 hours after randomization.

Tenecteplase (0.155 mg per dose) will be administered into the hematoma cavity through the drainage catheter after postoperative CT confirms hematoma stability, for up to three doses.

Otros nombres:
  • rhTNK-tPA

Standard medical treatment includes blood pressure management, intracranial pressure management, respiratory support, nutritional support, and rehabilitation.

Comparador activo: Standard Medical Treatment

Standard medical treatment includes blood pressure management, intracranial pressure management, respiratory support, nutritional support, and rehabilitation.

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Proportion of Participants With GCS Score >8
Periodo de tiempo: 90 days after randomization

Proportion of participants with a Glasgow Coma Scale (GCS) score greater than 8 at 90 days.

90 days after randomization
All-Cause Mortality
Periodo de tiempo: Within 30 days after randomization.

Proportion of participants who die from any cause within 30 days after randomization.

Within 30 days after randomization.

Medidas de resultado secundarias

Medida de resultado
Periodo de tiempo
7-Day All-Cause Mortality
Periodo de tiempo: Within 7 days
Within 7 days
Symptomatic Rebleeding
Periodo de tiempo: Within 72 hours after tenecteplase administration
Within 72 hours after tenecteplase administration
Intracranial Bacterial Infection
Periodo de tiempo: Within 30 days
Within 30 days
Serious Adverse Events (SAEs)
Periodo de tiempo: Within 30 days
Within 30 days
Adverse Events (AEs)
Periodo de tiempo: Within 30 days
Within 30 days
Serious Adverse Events (SAEs)
Periodo de tiempo: Within 365 days
Within 365 days
Adverse Events (AEs)
Periodo de tiempo: Within 365 days
Within 365 days
Proportion With GCS Increase ≥3 Points
Periodo de tiempo: 30 days
30 days
Proportion With Recovery of Consciousness
Periodo de tiempo: 30 days
30 days
Proportion With mRS 0-3
Periodo de tiempo: 90 days
90 days
Proportion With mRS 0-3
Periodo de tiempo: 365 days
365 days
Change in GCS Score Over Time
Periodo de tiempo: From baseline through 90 days after randomization
From baseline through 90 days after randomization

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

1 de abril de 2026

Finalización primaria (Estimado)

31 de diciembre de 2028

Finalización del estudio (Estimado)

31 de diciembre de 2028

Fechas de registro del estudio

Enviado por primera vez

10 de noviembre de 2026

Primero enviado que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Publicado por primera vez (Actual)

16 de noviembre de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

16 de noviembre de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

10 de noviembre de 2026

Última verificación

1 de noviembre de 2026

Más información

Términos relacionados con este estudio

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir